Global Filgrastim and Biosimilars Market Growth 2026-2032
The global Filgrastim and Biosimilars market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Filgrastim is a recombinant form of Granulocyte-Colony Stimulating Factor (G-CSF) that stimulates the bone marrow to increase production of neutrophils, essential white blood cells that fight infections. Biosimilars of filgrastim are biologic drugs highly similar to the original filgrastim product in terms of safety, efficacy, and potency but are typically more cost-effective.They are commonly used to manage neutropenia, particularly in patients undergoing chemotherapy, to lower infection risk.
United States market for Filgrastim and Biosimilars is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Filgrastim and Biosimilars is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Filgrastim and Biosimilars is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Filgrastim and Biosimilars players cover Amgen, Pfizer, Tanvex BioPharma, Kashiv BioSciences, Sandoz, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Filgrastim and Biosimilars Industry Forecast” looks at past sales and reviews total world Filgrastim and Biosimilars sales in 2025, providing a comprehensive analysis by region and market sector of projected Filgrastim and Biosimilars sales for 2026 through 2032. With Filgrastim and Biosimilars sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Filgrastim and Biosimilars industry.
This Insight Report provides a comprehensive analysis of the global Filgrastim and Biosimilars landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Filgrastim and Biosimilars portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Filgrastim and Biosimilars market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Filgrastim and Biosimilars and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Filgrastim and Biosimilars.
This report presents a comprehensive overview, market shares, and growth opportunities of Filgrastim and Biosimilars market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Filgrastim and Biosimilars market?
What factors are driving Filgrastim and Biosimilars market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Filgrastim and Biosimilars market opportunities vary by end market size?
How does Filgrastim and Biosimilars break out by Type, by Application?
The report requires updating with new data and is sent in 48 hours after order is placed.
Filgrastim is a recombinant form of Granulocyte-Colony Stimulating Factor (G-CSF) that stimulates the bone marrow to increase production of neutrophils, essential white blood cells that fight infections. Biosimilars of filgrastim are biologic drugs highly similar to the original filgrastim product in terms of safety, efficacy, and potency but are typically more cost-effective.They are commonly used to manage neutropenia, particularly in patients undergoing chemotherapy, to lower infection risk.
United States market for Filgrastim and Biosimilars is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Filgrastim and Biosimilars is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Filgrastim and Biosimilars is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Filgrastim and Biosimilars players cover Amgen, Pfizer, Tanvex BioPharma, Kashiv BioSciences, Sandoz, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Filgrastim and Biosimilars Industry Forecast” looks at past sales and reviews total world Filgrastim and Biosimilars sales in 2025, providing a comprehensive analysis by region and market sector of projected Filgrastim and Biosimilars sales for 2026 through 2032. With Filgrastim and Biosimilars sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Filgrastim and Biosimilars industry.
This Insight Report provides a comprehensive analysis of the global Filgrastim and Biosimilars landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Filgrastim and Biosimilars portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Filgrastim and Biosimilars market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Filgrastim and Biosimilars and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Filgrastim and Biosimilars.
This report presents a comprehensive overview, market shares, and growth opportunities of Filgrastim and Biosimilars market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Single-use Vials
- Prefilled Syringes
- Hospital and Clinic
- Pharmacy
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Amgen
- Pfizer
- Tanvex BioPharma
- Kashiv BioSciences
- Sandoz
- Teva
- Qilu Pharmaceutical
- Harbin Pharmaceutical Group
- Chengdu Institute of Biological Products
- CSPC Baike Biopharma
- Shanghai Sunway Biotech
- Changchun GeneScience Pharmaceutical
- Amoytop Biotech
- North China Pharmaceutical
- Kexing Biopharm
- SL Pharm
- Hangzhou Jiuyuan Gene Engineering
- Jiangsu Wuzhong Pharmaceutical
What is the 10-year outlook for the global Filgrastim and Biosimilars market?
What factors are driving Filgrastim and Biosimilars market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Filgrastim and Biosimilars market opportunities vary by end market size?
How does Filgrastim and Biosimilars break out by Type, by Application?
The report requires updating with new data and is sent in 48 hours after order is placed.
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Filgrastim and Biosimilars Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Filgrastim and Biosimilars by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Filgrastim and Biosimilars by Country/Region, 2021, 2025 & 2032
2.2 Filgrastim and Biosimilars Segment by Type
2.2.1 Single-use Vials
2.2.2 Prefilled Syringes
2.2.3 Filgrastim and Biosimilars Sales by Type
2.2.3.1 Global Filgrastim and Biosimilars Sales Market Share by Type (2021-2026)
2.2.3.2 Global Filgrastim and Biosimilars Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Filgrastim and Biosimilars Sale Price by Type (2021-2026)
2.3 Filgrastim and Biosimilars Segment by Application
2.3.1 Hospital and Clinic
2.3.2 Pharmacy
2.3.3 Other
2.3.4 Filgrastim and Biosimilars Sales by Application
2.3.4.1 Global Filgrastim and Biosimilars Sale Market Share by Application (2021-2026)
2.3.4.2 Global Filgrastim and Biosimilars Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Filgrastim and Biosimilars Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Filgrastim and Biosimilars Breakdown Data by Company
3.1.1 Global Filgrastim and Biosimilars Annual Sales by Company (2021-2026)
3.1.2 Global Filgrastim and Biosimilars Sales Market Share by Company (2021-2026)
3.2 Global Filgrastim and Biosimilars Annual Revenue by Company (2021-2026)
3.2.1 Global Filgrastim and Biosimilars Revenue by Company (2021-2026)
3.2.2 Global Filgrastim and Biosimilars Revenue Market Share by Company (2021-2026)
3.3 Global Filgrastim and Biosimilars Sale Price by Company
3.4 Key Manufacturers Filgrastim and Biosimilars Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Filgrastim and Biosimilars Product Location Distribution
3.4.2 Players Filgrastim and Biosimilars Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR FILGRASTIM AND BIOSIMILARS BY GEOGRAPHIC REGION
4.1 World Historic Filgrastim and Biosimilars Market Size by Geographic Region (2021-2026)
4.1.1 Global Filgrastim and Biosimilars Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Filgrastim and Biosimilars Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Filgrastim and Biosimilars Market Size by Country/Region (2021-2026)
4.2.1 Global Filgrastim and Biosimilars Annual Sales by Country/Region (2021-2026)
4.2.2 Global Filgrastim and Biosimilars Annual Revenue by Country/Region (2021-2026)
4.3 Americas Filgrastim and Biosimilars Sales Growth
4.4 APAC Filgrastim and Biosimilars Sales Growth
4.5 Europe Filgrastim and Biosimilars Sales Growth
4.6 Middle East & Africa Filgrastim and Biosimilars Sales Growth
5 AMERICAS
5.1 Americas Filgrastim and Biosimilars Sales by Country
5.1.1 Americas Filgrastim and Biosimilars Sales by Country (2021-2026)
5.1.2 Americas Filgrastim and Biosimilars Revenue by Country (2021-2026)
5.2 Americas Filgrastim and Biosimilars Sales by Type (2021-2026)
5.3 Americas Filgrastim and Biosimilars Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Filgrastim and Biosimilars Sales by Region
6.1.1 APAC Filgrastim and Biosimilars Sales by Region (2021-2026)
6.1.2 APAC Filgrastim and Biosimilars Revenue by Region (2021-2026)
6.2 APAC Filgrastim and Biosimilars Sales by Type (2021-2026)
6.3 APAC Filgrastim and Biosimilars Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Filgrastim and Biosimilars by Country
7.1.1 Europe Filgrastim and Biosimilars Sales by Country (2021-2026)
7.1.2 Europe Filgrastim and Biosimilars Revenue by Country (2021-2026)
7.2 Europe Filgrastim and Biosimilars Sales by Type (2021-2026)
7.3 Europe Filgrastim and Biosimilars Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Filgrastim and Biosimilars by Country
8.1.1 Middle East & Africa Filgrastim and Biosimilars Sales by Country (2021-2026)
8.1.2 Middle East & Africa Filgrastim and Biosimilars Revenue by Country (2021-2026)
8.2 Middle East & Africa Filgrastim and Biosimilars Sales by Type (2021-2026)
8.3 Middle East & Africa Filgrastim and Biosimilars Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Filgrastim and Biosimilars
10.3 Manufacturing Process Analysis of Filgrastim and Biosimilars
10.4 Industry Chain Structure of Filgrastim and Biosimilars
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Filgrastim and Biosimilars Distributors
11.3 Filgrastim and Biosimilars Customer
12 WORLD FORECAST REVIEW FOR FILGRASTIM AND BIOSIMILARS BY GEOGRAPHIC REGION
12.1 Global Filgrastim and Biosimilars Market Size Forecast by Region
12.1.1 Global Filgrastim and Biosimilars Forecast by Region (2027-2032)
12.1.2 Global Filgrastim and Biosimilars Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Filgrastim and Biosimilars Forecast by Type (2027-2032)
12.7 Global Filgrastim and Biosimilars Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Amgen
13.1.1 Amgen Company Information
13.1.2 Amgen Filgrastim and Biosimilars Product Portfolios and Specifications
13.1.3 Amgen Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Amgen Main Business Overview
13.1.5 Amgen Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Filgrastim and Biosimilars Product Portfolios and Specifications
13.2.3 Pfizer Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Tanvex BioPharma
13.3.1 Tanvex BioPharma Company Information
13.3.2 Tanvex BioPharma Filgrastim and Biosimilars Product Portfolios and Specifications
13.3.3 Tanvex BioPharma Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Tanvex BioPharma Main Business Overview
13.3.5 Tanvex BioPharma Latest Developments
13.4 Kashiv BioSciences
13.4.1 Kashiv BioSciences Company Information
13.4.2 Kashiv BioSciences Filgrastim and Biosimilars Product Portfolios and Specifications
13.4.3 Kashiv BioSciences Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Kashiv BioSciences Main Business Overview
13.4.5 Kashiv BioSciences Latest Developments
13.5 Sandoz
13.5.1 Sandoz Company Information
13.5.2 Sandoz Filgrastim and Biosimilars Product Portfolios and Specifications
13.5.3 Sandoz Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Sandoz Main Business Overview
13.5.5 Sandoz Latest Developments
13.6 Teva
13.6.1 Teva Company Information
13.6.2 Teva Filgrastim and Biosimilars Product Portfolios and Specifications
13.6.3 Teva Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Teva Main Business Overview
13.6.5 Teva Latest Developments
13.7 Qilu Pharmaceutical
13.7.1 Qilu Pharmaceutical Company Information
13.7.2 Qilu Pharmaceutical Filgrastim and Biosimilars Product Portfolios and Specifications
13.7.3 Qilu Pharmaceutical Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Qilu Pharmaceutical Main Business Overview
13.7.5 Qilu Pharmaceutical Latest Developments
13.8 Harbin Pharmaceutical Group
13.8.1 Harbin Pharmaceutical Group Company Information
13.8.2 Harbin Pharmaceutical Group Filgrastim and Biosimilars Product Portfolios and Specifications
13.8.3 Harbin Pharmaceutical Group Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Harbin Pharmaceutical Group Main Business Overview
13.8.5 Harbin Pharmaceutical Group Latest Developments
13.9 Chengdu Institute of Biological Products
13.9.1 Chengdu Institute of Biological Products Company Information
13.9.2 Chengdu Institute of Biological Products Filgrastim and Biosimilars Product Portfolios and Specifications
13.9.3 Chengdu Institute of Biological Products Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Chengdu Institute of Biological Products Main Business Overview
13.9.5 Chengdu Institute of Biological Products Latest Developments
13.10 CSPC Baike Biopharma
13.10.1 CSPC Baike Biopharma Company Information
13.10.2 CSPC Baike Biopharma Filgrastim and Biosimilars Product Portfolios and Specifications
13.10.3 CSPC Baike Biopharma Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 CSPC Baike Biopharma Main Business Overview
13.10.5 CSPC Baike Biopharma Latest Developments
13.11 Shanghai Sunway Biotech
13.11.1 Shanghai Sunway Biotech Company Information
13.11.2 Shanghai Sunway Biotech Filgrastim and Biosimilars Product Portfolios and Specifications
13.11.3 Shanghai Sunway Biotech Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Shanghai Sunway Biotech Main Business Overview
13.11.5 Shanghai Sunway Biotech Latest Developments
13.12 Changchun GeneScience Pharmaceutical
13.12.1 Changchun GeneScience Pharmaceutical Company Information
13.12.2 Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Product Portfolios and Specifications
13.12.3 Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Changchun GeneScience Pharmaceutical Main Business Overview
13.12.5 Changchun GeneScience Pharmaceutical Latest Developments
13.13 Amoytop Biotech
13.13.1 Amoytop Biotech Company Information
13.13.2 Amoytop Biotech Filgrastim and Biosimilars Product Portfolios and Specifications
13.13.3 Amoytop Biotech Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Amoytop Biotech Main Business Overview
13.13.5 Amoytop Biotech Latest Developments
13.14 North China Pharmaceutical
13.14.1 North China Pharmaceutical Company Information
13.14.2 North China Pharmaceutical Filgrastim and Biosimilars Product Portfolios and Specifications
13.14.3 North China Pharmaceutical Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 North China Pharmaceutical Main Business Overview
13.14.5 North China Pharmaceutical Latest Developments
13.15 Kexing Biopharm
13.15.1 Kexing Biopharm Company Information
13.15.2 Kexing Biopharm Filgrastim and Biosimilars Product Portfolios and Specifications
13.15.3 Kexing Biopharm Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Kexing Biopharm Main Business Overview
13.15.5 Kexing Biopharm Latest Developments
13.16 SL Pharm
13.16.1 SL Pharm Company Information
13.16.2 SL Pharm Filgrastim and Biosimilars Product Portfolios and Specifications
13.16.3 SL Pharm Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 SL Pharm Main Business Overview
13.16.5 SL Pharm Latest Developments
13.17 Hangzhou Jiuyuan Gene Engineering
13.17.1 Hangzhou Jiuyuan Gene Engineering Company Information
13.17.2 Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Product Portfolios and Specifications
13.17.3 Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Hangzhou Jiuyuan Gene Engineering Main Business Overview
13.17.5 Hangzhou Jiuyuan Gene Engineering Latest Developments
13.18 Jiangsu Wuzhong Pharmaceutical
13.18.1 Jiangsu Wuzhong Pharmaceutical Company Information
13.18.2 Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Product Portfolios and Specifications
13.18.3 Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Jiangsu Wuzhong Pharmaceutical Main Business Overview
13.18.5 Jiangsu Wuzhong Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Filgrastim and Biosimilars Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Filgrastim and Biosimilars by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Filgrastim and Biosimilars by Country/Region, 2021, 2025 & 2032
2.2 Filgrastim and Biosimilars Segment by Type
2.2.1 Single-use Vials
2.2.2 Prefilled Syringes
2.2.3 Filgrastim and Biosimilars Sales by Type
2.2.3.1 Global Filgrastim and Biosimilars Sales Market Share by Type (2021-2026)
2.2.3.2 Global Filgrastim and Biosimilars Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Filgrastim and Biosimilars Sale Price by Type (2021-2026)
2.3 Filgrastim and Biosimilars Segment by Application
2.3.1 Hospital and Clinic
2.3.2 Pharmacy
2.3.3 Other
2.3.4 Filgrastim and Biosimilars Sales by Application
2.3.4.1 Global Filgrastim and Biosimilars Sale Market Share by Application (2021-2026)
2.3.4.2 Global Filgrastim and Biosimilars Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Filgrastim and Biosimilars Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Filgrastim and Biosimilars Breakdown Data by Company
3.1.1 Global Filgrastim and Biosimilars Annual Sales by Company (2021-2026)
3.1.2 Global Filgrastim and Biosimilars Sales Market Share by Company (2021-2026)
3.2 Global Filgrastim and Biosimilars Annual Revenue by Company (2021-2026)
3.2.1 Global Filgrastim and Biosimilars Revenue by Company (2021-2026)
3.2.2 Global Filgrastim and Biosimilars Revenue Market Share by Company (2021-2026)
3.3 Global Filgrastim and Biosimilars Sale Price by Company
3.4 Key Manufacturers Filgrastim and Biosimilars Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Filgrastim and Biosimilars Product Location Distribution
3.4.2 Players Filgrastim and Biosimilars Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR FILGRASTIM AND BIOSIMILARS BY GEOGRAPHIC REGION
4.1 World Historic Filgrastim and Biosimilars Market Size by Geographic Region (2021-2026)
4.1.1 Global Filgrastim and Biosimilars Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Filgrastim and Biosimilars Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Filgrastim and Biosimilars Market Size by Country/Region (2021-2026)
4.2.1 Global Filgrastim and Biosimilars Annual Sales by Country/Region (2021-2026)
4.2.2 Global Filgrastim and Biosimilars Annual Revenue by Country/Region (2021-2026)
4.3 Americas Filgrastim and Biosimilars Sales Growth
4.4 APAC Filgrastim and Biosimilars Sales Growth
4.5 Europe Filgrastim and Biosimilars Sales Growth
4.6 Middle East & Africa Filgrastim and Biosimilars Sales Growth
5 AMERICAS
5.1 Americas Filgrastim and Biosimilars Sales by Country
5.1.1 Americas Filgrastim and Biosimilars Sales by Country (2021-2026)
5.1.2 Americas Filgrastim and Biosimilars Revenue by Country (2021-2026)
5.2 Americas Filgrastim and Biosimilars Sales by Type (2021-2026)
5.3 Americas Filgrastim and Biosimilars Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Filgrastim and Biosimilars Sales by Region
6.1.1 APAC Filgrastim and Biosimilars Sales by Region (2021-2026)
6.1.2 APAC Filgrastim and Biosimilars Revenue by Region (2021-2026)
6.2 APAC Filgrastim and Biosimilars Sales by Type (2021-2026)
6.3 APAC Filgrastim and Biosimilars Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Filgrastim and Biosimilars by Country
7.1.1 Europe Filgrastim and Biosimilars Sales by Country (2021-2026)
7.1.2 Europe Filgrastim and Biosimilars Revenue by Country (2021-2026)
7.2 Europe Filgrastim and Biosimilars Sales by Type (2021-2026)
7.3 Europe Filgrastim and Biosimilars Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Filgrastim and Biosimilars by Country
8.1.1 Middle East & Africa Filgrastim and Biosimilars Sales by Country (2021-2026)
8.1.2 Middle East & Africa Filgrastim and Biosimilars Revenue by Country (2021-2026)
8.2 Middle East & Africa Filgrastim and Biosimilars Sales by Type (2021-2026)
8.3 Middle East & Africa Filgrastim and Biosimilars Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Filgrastim and Biosimilars
10.3 Manufacturing Process Analysis of Filgrastim and Biosimilars
10.4 Industry Chain Structure of Filgrastim and Biosimilars
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Filgrastim and Biosimilars Distributors
11.3 Filgrastim and Biosimilars Customer
12 WORLD FORECAST REVIEW FOR FILGRASTIM AND BIOSIMILARS BY GEOGRAPHIC REGION
12.1 Global Filgrastim and Biosimilars Market Size Forecast by Region
12.1.1 Global Filgrastim and Biosimilars Forecast by Region (2027-2032)
12.1.2 Global Filgrastim and Biosimilars Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Filgrastim and Biosimilars Forecast by Type (2027-2032)
12.7 Global Filgrastim and Biosimilars Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Amgen
13.1.1 Amgen Company Information
13.1.2 Amgen Filgrastim and Biosimilars Product Portfolios and Specifications
13.1.3 Amgen Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Amgen Main Business Overview
13.1.5 Amgen Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Filgrastim and Biosimilars Product Portfolios and Specifications
13.2.3 Pfizer Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Tanvex BioPharma
13.3.1 Tanvex BioPharma Company Information
13.3.2 Tanvex BioPharma Filgrastim and Biosimilars Product Portfolios and Specifications
13.3.3 Tanvex BioPharma Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Tanvex BioPharma Main Business Overview
13.3.5 Tanvex BioPharma Latest Developments
13.4 Kashiv BioSciences
13.4.1 Kashiv BioSciences Company Information
13.4.2 Kashiv BioSciences Filgrastim and Biosimilars Product Portfolios and Specifications
13.4.3 Kashiv BioSciences Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Kashiv BioSciences Main Business Overview
13.4.5 Kashiv BioSciences Latest Developments
13.5 Sandoz
13.5.1 Sandoz Company Information
13.5.2 Sandoz Filgrastim and Biosimilars Product Portfolios and Specifications
13.5.3 Sandoz Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Sandoz Main Business Overview
13.5.5 Sandoz Latest Developments
13.6 Teva
13.6.1 Teva Company Information
13.6.2 Teva Filgrastim and Biosimilars Product Portfolios and Specifications
13.6.3 Teva Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Teva Main Business Overview
13.6.5 Teva Latest Developments
13.7 Qilu Pharmaceutical
13.7.1 Qilu Pharmaceutical Company Information
13.7.2 Qilu Pharmaceutical Filgrastim and Biosimilars Product Portfolios and Specifications
13.7.3 Qilu Pharmaceutical Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Qilu Pharmaceutical Main Business Overview
13.7.5 Qilu Pharmaceutical Latest Developments
13.8 Harbin Pharmaceutical Group
13.8.1 Harbin Pharmaceutical Group Company Information
13.8.2 Harbin Pharmaceutical Group Filgrastim and Biosimilars Product Portfolios and Specifications
13.8.3 Harbin Pharmaceutical Group Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Harbin Pharmaceutical Group Main Business Overview
13.8.5 Harbin Pharmaceutical Group Latest Developments
13.9 Chengdu Institute of Biological Products
13.9.1 Chengdu Institute of Biological Products Company Information
13.9.2 Chengdu Institute of Biological Products Filgrastim and Biosimilars Product Portfolios and Specifications
13.9.3 Chengdu Institute of Biological Products Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Chengdu Institute of Biological Products Main Business Overview
13.9.5 Chengdu Institute of Biological Products Latest Developments
13.10 CSPC Baike Biopharma
13.10.1 CSPC Baike Biopharma Company Information
13.10.2 CSPC Baike Biopharma Filgrastim and Biosimilars Product Portfolios and Specifications
13.10.3 CSPC Baike Biopharma Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 CSPC Baike Biopharma Main Business Overview
13.10.5 CSPC Baike Biopharma Latest Developments
13.11 Shanghai Sunway Biotech
13.11.1 Shanghai Sunway Biotech Company Information
13.11.2 Shanghai Sunway Biotech Filgrastim and Biosimilars Product Portfolios and Specifications
13.11.3 Shanghai Sunway Biotech Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Shanghai Sunway Biotech Main Business Overview
13.11.5 Shanghai Sunway Biotech Latest Developments
13.12 Changchun GeneScience Pharmaceutical
13.12.1 Changchun GeneScience Pharmaceutical Company Information
13.12.2 Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Product Portfolios and Specifications
13.12.3 Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Changchun GeneScience Pharmaceutical Main Business Overview
13.12.5 Changchun GeneScience Pharmaceutical Latest Developments
13.13 Amoytop Biotech
13.13.1 Amoytop Biotech Company Information
13.13.2 Amoytop Biotech Filgrastim and Biosimilars Product Portfolios and Specifications
13.13.3 Amoytop Biotech Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Amoytop Biotech Main Business Overview
13.13.5 Amoytop Biotech Latest Developments
13.14 North China Pharmaceutical
13.14.1 North China Pharmaceutical Company Information
13.14.2 North China Pharmaceutical Filgrastim and Biosimilars Product Portfolios and Specifications
13.14.3 North China Pharmaceutical Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 North China Pharmaceutical Main Business Overview
13.14.5 North China Pharmaceutical Latest Developments
13.15 Kexing Biopharm
13.15.1 Kexing Biopharm Company Information
13.15.2 Kexing Biopharm Filgrastim and Biosimilars Product Portfolios and Specifications
13.15.3 Kexing Biopharm Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Kexing Biopharm Main Business Overview
13.15.5 Kexing Biopharm Latest Developments
13.16 SL Pharm
13.16.1 SL Pharm Company Information
13.16.2 SL Pharm Filgrastim and Biosimilars Product Portfolios and Specifications
13.16.3 SL Pharm Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 SL Pharm Main Business Overview
13.16.5 SL Pharm Latest Developments
13.17 Hangzhou Jiuyuan Gene Engineering
13.17.1 Hangzhou Jiuyuan Gene Engineering Company Information
13.17.2 Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Product Portfolios and Specifications
13.17.3 Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Hangzhou Jiuyuan Gene Engineering Main Business Overview
13.17.5 Hangzhou Jiuyuan Gene Engineering Latest Developments
13.18 Jiangsu Wuzhong Pharmaceutical
13.18.1 Jiangsu Wuzhong Pharmaceutical Company Information
13.18.2 Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Product Portfolios and Specifications
13.18.3 Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Jiangsu Wuzhong Pharmaceutical Main Business Overview
13.18.5 Jiangsu Wuzhong Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Filgrastim and Biosimilars Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Filgrastim and Biosimilars Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Single-use Vials
Table 4. Major Players of Prefilled Syringes
Table 5. Global Filgrastim and Biosimilars Sales by Type (2021-2026) & (K Units)
Table 6. Global Filgrastim and Biosimilars Sales Market Share by Type (2021-2026)
Table 7. Global Filgrastim and Biosimilars Revenue by Type (2021-2026) & ($ million)
Table 8. Global Filgrastim and Biosimilars Revenue Market Share by Type (2021-2026)
Table 9. Global Filgrastim and Biosimilars Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Filgrastim and Biosimilars Sale by Application (2021-2026) & (K Units)
Table 11. Global Filgrastim and Biosimilars Sale Market Share by Application (2021-2026)
Table 12. Global Filgrastim and Biosimilars Revenue by Application (2021-2026) & ($ million)
Table 13. Global Filgrastim and Biosimilars Revenue Market Share by Application (2021-2026)
Table 14. Global Filgrastim and Biosimilars Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Filgrastim and Biosimilars Sales by Company (2021-2026) & (K Units)
Table 16. Global Filgrastim and Biosimilars Sales Market Share by Company (2021-2026)
Table 17. Global Filgrastim and Biosimilars Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Filgrastim and Biosimilars Revenue Market Share by Company (2021-2026)
Table 19. Global Filgrastim and Biosimilars Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Filgrastim and Biosimilars Producing Area Distribution and Sales Area
Table 21. Players Filgrastim and Biosimilars Products Offered
Table 22. Filgrastim and Biosimilars Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Filgrastim and Biosimilars Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Filgrastim and Biosimilars Sales Market Share Geographic Region (2021-2026)
Table 27. Global Filgrastim and Biosimilars Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Filgrastim and Biosimilars Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Filgrastim and Biosimilars Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Filgrastim and Biosimilars Sales Market Share by Country/Region (2021-2026)
Table 31. Global Filgrastim and Biosimilars Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Filgrastim and Biosimilars Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units)
Table 34. Americas Filgrastim and Biosimilars Sales Market Share by Country (2021-2026)
Table 35. Americas Filgrastim and Biosimilars Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Filgrastim and Biosimilars Sales by Type (2021-2026) & (K Units)
Table 37. Americas Filgrastim and Biosimilars Sales by Application (2021-2026) & (K Units)
Table 38. APAC Filgrastim and Biosimilars Sales by Region (2021-2026) & (K Units)
Table 39. APAC Filgrastim and Biosimilars Sales Market Share by Region (2021-2026)
Table 40. APAC Filgrastim and Biosimilars Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Filgrastim and Biosimilars Sales by Type (2021-2026) & (K Units)
Table 42. APAC Filgrastim and Biosimilars Sales by Application (2021-2026) & (K Units)
Table 43. Europe Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units)
Table 44. Europe Filgrastim and Biosimilars Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Filgrastim and Biosimilars Sales by Type (2021-2026) & (K Units)
Table 46. Europe Filgrastim and Biosimilars Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Filgrastim and Biosimilars Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Filgrastim and Biosimilars Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Filgrastim and Biosimilars Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Filgrastim and Biosimilars
Table 52. Key Market Challenges & Risks of Filgrastim and Biosimilars
Table 53. Key Industry Trends of Filgrastim and Biosimilars
Table 54. Filgrastim and Biosimilars Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Filgrastim and Biosimilars Distributors List
Table 57. Filgrastim and Biosimilars Customer List
Table 58. Global Filgrastim and Biosimilars Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Filgrastim and Biosimilars Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Filgrastim and Biosimilars Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Filgrastim and Biosimilars Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Filgrastim and Biosimilars Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Filgrastim and Biosimilars Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Filgrastim and Biosimilars Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Filgrastim and Biosimilars Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Filgrastim and Biosimilars Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Filgrastim and Biosimilars Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Filgrastim and Biosimilars Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Filgrastim and Biosimilars Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Filgrastim and Biosimilars Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Filgrastim and Biosimilars Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Amgen Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 73. Amgen Filgrastim and Biosimilars Product Portfolios and Specifications
Table 74. Amgen Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Amgen Main Business
Table 76. Amgen Latest Developments
Table 77. Pfizer Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 78. Pfizer Filgrastim and Biosimilars Product Portfolios and Specifications
Table 79. Pfizer Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Pfizer Main Business
Table 81. Pfizer Latest Developments
Table 82. Tanvex BioPharma Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 83. Tanvex BioPharma Filgrastim and Biosimilars Product Portfolios and Specifications
Table 84. Tanvex BioPharma Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Tanvex BioPharma Main Business
Table 86. Tanvex BioPharma Latest Developments
Table 87. Kashiv BioSciences Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 88. Kashiv BioSciences Filgrastim and Biosimilars Product Portfolios and Specifications
Table 89. Kashiv BioSciences Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Kashiv BioSciences Main Business
Table 91. Kashiv BioSciences Latest Developments
Table 92. Sandoz Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 93. Sandoz Filgrastim and Biosimilars Product Portfolios and Specifications
Table 94. Sandoz Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Sandoz Main Business
Table 96. Sandoz Latest Developments
Table 97. Teva Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 98. Teva Filgrastim and Biosimilars Product Portfolios and Specifications
Table 99. Teva Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Teva Main Business
Table 101. Teva Latest Developments
Table 102. Qilu Pharmaceutical Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 103. Qilu Pharmaceutical Filgrastim and Biosimilars Product Portfolios and Specifications
Table 104. Qilu Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Qilu Pharmaceutical Main Business
Table 106. Qilu Pharmaceutical Latest Developments
Table 107. Harbin Pharmaceutical Group Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 108. Harbin Pharmaceutical Group Filgrastim and Biosimilars Product Portfolios and Specifications
Table 109. Harbin Pharmaceutical Group Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Harbin Pharmaceutical Group Main Business
Table 111. Harbin Pharmaceutical Group Latest Developments
Table 112. Chengdu Institute of Biological Products Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 113. Chengdu Institute of Biological Products Filgrastim and Biosimilars Product Portfolios and Specifications
Table 114. Chengdu Institute of Biological Products Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Chengdu Institute of Biological Products Main Business
Table 116. Chengdu Institute of Biological Products Latest Developments
Table 117. CSPC Baike Biopharma Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 118. CSPC Baike Biopharma Filgrastim and Biosimilars Product Portfolios and Specifications
Table 119. CSPC Baike Biopharma Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. CSPC Baike Biopharma Main Business
Table 121. CSPC Baike Biopharma Latest Developments
Table 122. Shanghai Sunway Biotech Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 123. Shanghai Sunway Biotech Filgrastim and Biosimilars Product Portfolios and Specifications
Table 124. Shanghai Sunway Biotech Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Shanghai Sunway Biotech Main Business
Table 126. Shanghai Sunway Biotech Latest Developments
Table 127. Changchun GeneScience Pharmaceutical Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 128. Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Product Portfolios and Specifications
Table 129. Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. Changchun GeneScience Pharmaceutical Main Business
Table 131. Changchun GeneScience Pharmaceutical Latest Developments
Table 132. Amoytop Biotech Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 133. Amoytop Biotech Filgrastim and Biosimilars Product Portfolios and Specifications
Table 134. Amoytop Biotech Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 135. Amoytop Biotech Main Business
Table 136. Amoytop Biotech Latest Developments
Table 137. North China Pharmaceutical Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 138. North China Pharmaceutical Filgrastim and Biosimilars Product Portfolios and Specifications
Table 139. North China Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 140. North China Pharmaceutical Main Business
Table 141. North China Pharmaceutical Latest Developments
Table 142. Kexing Biopharm Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 143. Kexing Biopharm Filgrastim and Biosimilars Product Portfolios and Specifications
Table 144. Kexing Biopharm Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 145. Kexing Biopharm Main Business
Table 146. Kexing Biopharm Latest Developments
Table 147. SL Pharm Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 148. SL Pharm Filgrastim and Biosimilars Product Portfolios and Specifications
Table 149. SL Pharm Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 150. SL Pharm Main Business
Table 151. SL Pharm Latest Developments
Table 152. Hangzhou Jiuyuan Gene Engineering Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 153. Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Product Portfolios and Specifications
Table 154. Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 155. Hangzhou Jiuyuan Gene Engineering Main Business
Table 156. Hangzhou Jiuyuan Gene Engineering Latest Developments
Table 157. Jiangsu Wuzhong Pharmaceutical Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 158. Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Product Portfolios and Specifications
Table 159. Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 160. Jiangsu Wuzhong Pharmaceutical Main Business
Table 161. Jiangsu Wuzhong Pharmaceutical Latest Developments
Table 1. Filgrastim and Biosimilars Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Filgrastim and Biosimilars Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Single-use Vials
Table 4. Major Players of Prefilled Syringes
Table 5. Global Filgrastim and Biosimilars Sales by Type (2021-2026) & (K Units)
Table 6. Global Filgrastim and Biosimilars Sales Market Share by Type (2021-2026)
Table 7. Global Filgrastim and Biosimilars Revenue by Type (2021-2026) & ($ million)
Table 8. Global Filgrastim and Biosimilars Revenue Market Share by Type (2021-2026)
Table 9. Global Filgrastim and Biosimilars Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Filgrastim and Biosimilars Sale by Application (2021-2026) & (K Units)
Table 11. Global Filgrastim and Biosimilars Sale Market Share by Application (2021-2026)
Table 12. Global Filgrastim and Biosimilars Revenue by Application (2021-2026) & ($ million)
Table 13. Global Filgrastim and Biosimilars Revenue Market Share by Application (2021-2026)
Table 14. Global Filgrastim and Biosimilars Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Filgrastim and Biosimilars Sales by Company (2021-2026) & (K Units)
Table 16. Global Filgrastim and Biosimilars Sales Market Share by Company (2021-2026)
Table 17. Global Filgrastim and Biosimilars Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Filgrastim and Biosimilars Revenue Market Share by Company (2021-2026)
Table 19. Global Filgrastim and Biosimilars Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Filgrastim and Biosimilars Producing Area Distribution and Sales Area
Table 21. Players Filgrastim and Biosimilars Products Offered
Table 22. Filgrastim and Biosimilars Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Filgrastim and Biosimilars Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Filgrastim and Biosimilars Sales Market Share Geographic Region (2021-2026)
Table 27. Global Filgrastim and Biosimilars Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Filgrastim and Biosimilars Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Filgrastim and Biosimilars Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Filgrastim and Biosimilars Sales Market Share by Country/Region (2021-2026)
Table 31. Global Filgrastim and Biosimilars Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Filgrastim and Biosimilars Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units)
Table 34. Americas Filgrastim and Biosimilars Sales Market Share by Country (2021-2026)
Table 35. Americas Filgrastim and Biosimilars Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Filgrastim and Biosimilars Sales by Type (2021-2026) & (K Units)
Table 37. Americas Filgrastim and Biosimilars Sales by Application (2021-2026) & (K Units)
Table 38. APAC Filgrastim and Biosimilars Sales by Region (2021-2026) & (K Units)
Table 39. APAC Filgrastim and Biosimilars Sales Market Share by Region (2021-2026)
Table 40. APAC Filgrastim and Biosimilars Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Filgrastim and Biosimilars Sales by Type (2021-2026) & (K Units)
Table 42. APAC Filgrastim and Biosimilars Sales by Application (2021-2026) & (K Units)
Table 43. Europe Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units)
Table 44. Europe Filgrastim and Biosimilars Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Filgrastim and Biosimilars Sales by Type (2021-2026) & (K Units)
Table 46. Europe Filgrastim and Biosimilars Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Filgrastim and Biosimilars Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Filgrastim and Biosimilars Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Filgrastim and Biosimilars Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Filgrastim and Biosimilars
Table 52. Key Market Challenges & Risks of Filgrastim and Biosimilars
Table 53. Key Industry Trends of Filgrastim and Biosimilars
Table 54. Filgrastim and Biosimilars Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Filgrastim and Biosimilars Distributors List
Table 57. Filgrastim and Biosimilars Customer List
Table 58. Global Filgrastim and Biosimilars Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Filgrastim and Biosimilars Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Filgrastim and Biosimilars Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Filgrastim and Biosimilars Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Filgrastim and Biosimilars Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Filgrastim and Biosimilars Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Filgrastim and Biosimilars Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Filgrastim and Biosimilars Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Filgrastim and Biosimilars Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Filgrastim and Biosimilars Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Filgrastim and Biosimilars Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Filgrastim and Biosimilars Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Filgrastim and Biosimilars Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Filgrastim and Biosimilars Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Amgen Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 73. Amgen Filgrastim and Biosimilars Product Portfolios and Specifications
Table 74. Amgen Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Amgen Main Business
Table 76. Amgen Latest Developments
Table 77. Pfizer Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 78. Pfizer Filgrastim and Biosimilars Product Portfolios and Specifications
Table 79. Pfizer Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Pfizer Main Business
Table 81. Pfizer Latest Developments
Table 82. Tanvex BioPharma Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 83. Tanvex BioPharma Filgrastim and Biosimilars Product Portfolios and Specifications
Table 84. Tanvex BioPharma Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Tanvex BioPharma Main Business
Table 86. Tanvex BioPharma Latest Developments
Table 87. Kashiv BioSciences Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 88. Kashiv BioSciences Filgrastim and Biosimilars Product Portfolios and Specifications
Table 89. Kashiv BioSciences Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Kashiv BioSciences Main Business
Table 91. Kashiv BioSciences Latest Developments
Table 92. Sandoz Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 93. Sandoz Filgrastim and Biosimilars Product Portfolios and Specifications
Table 94. Sandoz Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Sandoz Main Business
Table 96. Sandoz Latest Developments
Table 97. Teva Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 98. Teva Filgrastim and Biosimilars Product Portfolios and Specifications
Table 99. Teva Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Teva Main Business
Table 101. Teva Latest Developments
Table 102. Qilu Pharmaceutical Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 103. Qilu Pharmaceutical Filgrastim and Biosimilars Product Portfolios and Specifications
Table 104. Qilu Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Qilu Pharmaceutical Main Business
Table 106. Qilu Pharmaceutical Latest Developments
Table 107. Harbin Pharmaceutical Group Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 108. Harbin Pharmaceutical Group Filgrastim and Biosimilars Product Portfolios and Specifications
Table 109. Harbin Pharmaceutical Group Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Harbin Pharmaceutical Group Main Business
Table 111. Harbin Pharmaceutical Group Latest Developments
Table 112. Chengdu Institute of Biological Products Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 113. Chengdu Institute of Biological Products Filgrastim and Biosimilars Product Portfolios and Specifications
Table 114. Chengdu Institute of Biological Products Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Chengdu Institute of Biological Products Main Business
Table 116. Chengdu Institute of Biological Products Latest Developments
Table 117. CSPC Baike Biopharma Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 118. CSPC Baike Biopharma Filgrastim and Biosimilars Product Portfolios and Specifications
Table 119. CSPC Baike Biopharma Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. CSPC Baike Biopharma Main Business
Table 121. CSPC Baike Biopharma Latest Developments
Table 122. Shanghai Sunway Biotech Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 123. Shanghai Sunway Biotech Filgrastim and Biosimilars Product Portfolios and Specifications
Table 124. Shanghai Sunway Biotech Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Shanghai Sunway Biotech Main Business
Table 126. Shanghai Sunway Biotech Latest Developments
Table 127. Changchun GeneScience Pharmaceutical Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 128. Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Product Portfolios and Specifications
Table 129. Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. Changchun GeneScience Pharmaceutical Main Business
Table 131. Changchun GeneScience Pharmaceutical Latest Developments
Table 132. Amoytop Biotech Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 133. Amoytop Biotech Filgrastim and Biosimilars Product Portfolios and Specifications
Table 134. Amoytop Biotech Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 135. Amoytop Biotech Main Business
Table 136. Amoytop Biotech Latest Developments
Table 137. North China Pharmaceutical Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 138. North China Pharmaceutical Filgrastim and Biosimilars Product Portfolios and Specifications
Table 139. North China Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 140. North China Pharmaceutical Main Business
Table 141. North China Pharmaceutical Latest Developments
Table 142. Kexing Biopharm Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 143. Kexing Biopharm Filgrastim and Biosimilars Product Portfolios and Specifications
Table 144. Kexing Biopharm Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 145. Kexing Biopharm Main Business
Table 146. Kexing Biopharm Latest Developments
Table 147. SL Pharm Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 148. SL Pharm Filgrastim and Biosimilars Product Portfolios and Specifications
Table 149. SL Pharm Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 150. SL Pharm Main Business
Table 151. SL Pharm Latest Developments
Table 152. Hangzhou Jiuyuan Gene Engineering Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 153. Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Product Portfolios and Specifications
Table 154. Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 155. Hangzhou Jiuyuan Gene Engineering Main Business
Table 156. Hangzhou Jiuyuan Gene Engineering Latest Developments
Table 157. Jiangsu Wuzhong Pharmaceutical Basic Information, Filgrastim and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 158. Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Product Portfolios and Specifications
Table 159. Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 160. Jiangsu Wuzhong Pharmaceutical Main Business
Table 161. Jiangsu Wuzhong Pharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Picture of Filgrastim and Biosimilars
Figure 2. Filgrastim and Biosimilars Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Filgrastim and Biosimilars Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Filgrastim and Biosimilars Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Filgrastim and Biosimilars Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Filgrastim and Biosimilars Sales Market Share by Country/Region (2025)
Figure 10. Filgrastim and Biosimilars Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Single-use Vials
Figure 12. Product Picture of Prefilled Syringes
Figure 13. Global Filgrastim and Biosimilars Sales Market Share by Type in 2026
Figure 14. Global Filgrastim and Biosimilars Revenue Market Share by Type (2021-2026)
Figure 15. Filgrastim and Biosimilars Consumed in Hospital and Clinic
Figure 16. Global Filgrastim and Biosimilars Market: Hospital and Clinic (2021-2026) & (K Units)
Figure 17. Filgrastim and Biosimilars Consumed in Pharmacy
Figure 18. Global Filgrastim and Biosimilars Market: Pharmacy (2021-2026) & (K Units)
Figure 19. Filgrastim and Biosimilars Consumed in Other
Figure 20. Global Filgrastim and Biosimilars Market: Other (2021-2026) & (K Units)
Figure 21. Global Filgrastim and Biosimilars Sale Market Share by Application (2025)
Figure 22. Global Filgrastim and Biosimilars Revenue Market Share by Application in 2026
Figure 23. Filgrastim and Biosimilars Sales by Company in 2026 (K Units)
Figure 24. Global Filgrastim and Biosimilars Sales Market Share by Company in 2026
Figure 25. Filgrastim and Biosimilars Revenue by Company in 2026 ($ millions)
Figure 26. Global Filgrastim and Biosimilars Revenue Market Share by Company in 2026
Figure 27. Global Filgrastim and Biosimilars Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Filgrastim and Biosimilars Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Filgrastim and Biosimilars Sales 2021-2026 (K Units)
Figure 30. Americas Filgrastim and Biosimilars Revenue 2021-2026 ($ millions)
Figure 31. APAC Filgrastim and Biosimilars Sales 2021-2026 (K Units)
Figure 32. APAC Filgrastim and Biosimilars Revenue 2021-2026 ($ millions)
Figure 33. Europe Filgrastim and Biosimilars Sales 2021-2026 (K Units)
Figure 34. Europe Filgrastim and Biosimilars Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Filgrastim and Biosimilars Sales 2021-2026 (K Units)
Figure 36. Middle East & Africa Filgrastim and Biosimilars Revenue 2021-2026 ($ millions)
Figure 37. Americas Filgrastim and Biosimilars Sales Market Share by Country in 2026
Figure 38. Americas Filgrastim and Biosimilars Revenue Market Share by Country (2021-2026)
Figure 39. Americas Filgrastim and Biosimilars Sales Market Share by Type (2021-2026)
Figure 40. Americas Filgrastim and Biosimilars Sales Market Share by Application (2021-2026)
Figure 41. United States Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Filgrastim and Biosimilars Sales Market Share by Region in 2026
Figure 46. APAC Filgrastim and Biosimilars Revenue Market Share by Region (2021-2026)
Figure 47. APAC Filgrastim and Biosimilars Sales Market Share by Type (2021-2026)
Figure 48. APAC Filgrastim and Biosimilars Sales Market Share by Application (2021-2026)
Figure 49. China Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 53. India Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Filgrastim and Biosimilars Sales Market Share by Country in 2026
Figure 57. Europe Filgrastim and Biosimilars Revenue Market Share by Country (2021-2026)
Figure 58. Europe Filgrastim and Biosimilars Sales Market Share by Type (2021-2026)
Figure 59. Europe Filgrastim and Biosimilars Sales Market Share by Application (2021-2026)
Figure 60. Germany Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 61. France Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Filgrastim and Biosimilars Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Filgrastim and Biosimilars Sales Market Share by Type (2021-2026)
Figure 67. Middle East & Africa Filgrastim and Biosimilars Sales Market Share by Application (2021-2026)
Figure 68. Egypt Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Filgrastim and Biosimilars in 2026
Figure 74. Manufacturing Process Analysis of Filgrastim and Biosimilars
Figure 75. Industry Chain Structure of Filgrastim and Biosimilars
Figure 76. Channels of Distribution
Figure 77. Global Filgrastim and Biosimilars Sales Market Forecast by Region (2027-2032)
Figure 78. Global Filgrastim and Biosimilars Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Filgrastim and Biosimilars Sales Market Share Forecast by Type (2027-2032)
Figure 80. Global Filgrastim and Biosimilars Revenue Market Share Forecast by Type (2027-2032)
Figure 81. Global Filgrastim and Biosimilars Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Filgrastim and Biosimilars Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Filgrastim and Biosimilars
Figure 2. Filgrastim and Biosimilars Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Filgrastim and Biosimilars Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Filgrastim and Biosimilars Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Filgrastim and Biosimilars Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Filgrastim and Biosimilars Sales Market Share by Country/Region (2025)
Figure 10. Filgrastim and Biosimilars Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Single-use Vials
Figure 12. Product Picture of Prefilled Syringes
Figure 13. Global Filgrastim and Biosimilars Sales Market Share by Type in 2026
Figure 14. Global Filgrastim and Biosimilars Revenue Market Share by Type (2021-2026)
Figure 15. Filgrastim and Biosimilars Consumed in Hospital and Clinic
Figure 16. Global Filgrastim and Biosimilars Market: Hospital and Clinic (2021-2026) & (K Units)
Figure 17. Filgrastim and Biosimilars Consumed in Pharmacy
Figure 18. Global Filgrastim and Biosimilars Market: Pharmacy (2021-2026) & (K Units)
Figure 19. Filgrastim and Biosimilars Consumed in Other
Figure 20. Global Filgrastim and Biosimilars Market: Other (2021-2026) & (K Units)
Figure 21. Global Filgrastim and Biosimilars Sale Market Share by Application (2025)
Figure 22. Global Filgrastim and Biosimilars Revenue Market Share by Application in 2026
Figure 23. Filgrastim and Biosimilars Sales by Company in 2026 (K Units)
Figure 24. Global Filgrastim and Biosimilars Sales Market Share by Company in 2026
Figure 25. Filgrastim and Biosimilars Revenue by Company in 2026 ($ millions)
Figure 26. Global Filgrastim and Biosimilars Revenue Market Share by Company in 2026
Figure 27. Global Filgrastim and Biosimilars Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Filgrastim and Biosimilars Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Filgrastim and Biosimilars Sales 2021-2026 (K Units)
Figure 30. Americas Filgrastim and Biosimilars Revenue 2021-2026 ($ millions)
Figure 31. APAC Filgrastim and Biosimilars Sales 2021-2026 (K Units)
Figure 32. APAC Filgrastim and Biosimilars Revenue 2021-2026 ($ millions)
Figure 33. Europe Filgrastim and Biosimilars Sales 2021-2026 (K Units)
Figure 34. Europe Filgrastim and Biosimilars Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Filgrastim and Biosimilars Sales 2021-2026 (K Units)
Figure 36. Middle East & Africa Filgrastim and Biosimilars Revenue 2021-2026 ($ millions)
Figure 37. Americas Filgrastim and Biosimilars Sales Market Share by Country in 2026
Figure 38. Americas Filgrastim and Biosimilars Revenue Market Share by Country (2021-2026)
Figure 39. Americas Filgrastim and Biosimilars Sales Market Share by Type (2021-2026)
Figure 40. Americas Filgrastim and Biosimilars Sales Market Share by Application (2021-2026)
Figure 41. United States Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Filgrastim and Biosimilars Sales Market Share by Region in 2026
Figure 46. APAC Filgrastim and Biosimilars Revenue Market Share by Region (2021-2026)
Figure 47. APAC Filgrastim and Biosimilars Sales Market Share by Type (2021-2026)
Figure 48. APAC Filgrastim and Biosimilars Sales Market Share by Application (2021-2026)
Figure 49. China Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 53. India Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Filgrastim and Biosimilars Sales Market Share by Country in 2026
Figure 57. Europe Filgrastim and Biosimilars Revenue Market Share by Country (2021-2026)
Figure 58. Europe Filgrastim and Biosimilars Sales Market Share by Type (2021-2026)
Figure 59. Europe Filgrastim and Biosimilars Sales Market Share by Application (2021-2026)
Figure 60. Germany Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 61. France Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Filgrastim and Biosimilars Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Filgrastim and Biosimilars Sales Market Share by Type (2021-2026)
Figure 67. Middle East & Africa Filgrastim and Biosimilars Sales Market Share by Application (2021-2026)
Figure 68. Egypt Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Filgrastim and Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Filgrastim and Biosimilars in 2026
Figure 74. Manufacturing Process Analysis of Filgrastim and Biosimilars
Figure 75. Industry Chain Structure of Filgrastim and Biosimilars
Figure 76. Channels of Distribution
Figure 77. Global Filgrastim and Biosimilars Sales Market Forecast by Region (2027-2032)
Figure 78. Global Filgrastim and Biosimilars Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Filgrastim and Biosimilars Sales Market Share Forecast by Type (2027-2032)
Figure 80. Global Filgrastim and Biosimilars Revenue Market Share Forecast by Type (2027-2032)
Figure 81. Global Filgrastim and Biosimilars Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Filgrastim and Biosimilars Revenue Market Share Forecast by Application (2027-2032)
